Gemcitabine chemotherapy is used for advanced cancers of the breast, lungs, ovaries, and pancreas. Learn about delivery, side effects, effectiveness, and more.

Gemcitabine has been used since 1997 as a treatment for advanced unresectable pancreatic cancer, and it is a potent radiosensitizer. Dr. Loehrer and colleagues examined the role, among patients ...

We report our experience with sequential intravesical combination chemotherapy using gemcitabine and mitomycin C (MMC) for non-muscle invasive bladder cancer (NMIBC). Methods: We performed a ...

Yes. The randomized phase 3 APACT trial was a well-designed adjuvant trial that evaluated the addition of nab-paclitaxel (Abraxane, Celgene) to gemcitabine — the combination was planned based ...

Gemcitabine as a single agent and the combination of gemcitabine and docetaxel have activity in patients with metastatic soft tissue sarcoma. To determine if the addition of docetaxel to gemcitabine ...

A patient who is receiving cisplatin and gemcitabine in 2 cycles for nonsmall-cell lung cancer (NSCLC) developed thrombocytosis (platelet count 800,000/mcL). There are no other side effects. Is it ...

People who have had pancreatic cancer removed surgically may have better survival time without disease progression if they are treated with gemcitabine (Gemzar) for 6 months.

Pancreatic cancer is the fourth leading cause of cancer death in the US, with over 35,000 deaths reported in 2009. 1 In 1997, gemcitabine became the standard of care for advanced disease and since ...

Prior to induction BCG, the gemcitabine-docetaxel group had a significantly higher proportion of patients with Ta/Tis (noninvasive) tumors compared with the BCG group (68.8% vs 52.2%), whereas the ...

Patients treated with gemcitabine plus cisplatin had significantly improved progression-free survival (median of 7.0 versus 5.6 months, P <0.0001), and overall survival (median of 29.1 versus 20.9 ...

London, UK, 9 March 2009 - The oncology product Gemcitabine, produced by Actavis Group, the international generic pharmaceuticals company, was launched in EU markets, at patent expiry. The launch ...